Clinical Trial

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

Name: A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation — clinical trial record (NCT06441084)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.

Trial Details

NCT Number	NCT06441084
Lead Sponsor	Nuwacell Biotechnologies Co., Ltd. Collaborators: Beijing Friendship Hospital
Conditions	Acute Myeloid Leukemia
Enrollment	15 participants
Start Date	2024-06-30
Primary Completion	2028-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-06-04